Non-HDL-C:血脂干预管理的新靶标

[1] Intensive lipid lowering with atorvastatin in patients with stable coronary disease. LaRosa JC,Grundy SM,Waters DD,et al. The New England Journal of Medicine . 2005

[2] Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins:a meta-analysis. Boekhold SM,Aresenault BJ,Mora S,et al. The Journal of The American Medical Association . 2012

[3] Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Cui Y,Blumenthal RS,Flaws JA,et al. Archives of Internal Medicine . 2001

[4] ESC/EAS Guidelines for the management of dyslipidaemias:theTask Force for the management of dyslipidaemias of theEuropean Society of Cardiology(ESC)and the EuropeanAtherosclerosis Society(EAS). European Association for Cardiovascular Prevention&RE-HABILITATION,,REINER Z,CATAPANO AL,et al. European Heart Journal . 2011

[5] Beyond Low-Density Lipoprotein Cholesterol[J] . Benoit J. Arsenault,Jamal S. Rana,Erik S.G. Stroes,Jean-Pierre Després,Prediman K. Shah,John J.P. Kastelein,Nicholas J. Wareham,S. Matthijs Boekholdt,Kay-Tee Khaw. &nbspJournal of the American College of Cardiology . 2010 (1)

[6] Non–High-Density Lipoprotein Cholesterol Levels Predict Five-Year Outcome in the Bypass Angioplasty Revascularization Investigation (BARI)[J] . Vera Bittner,Regina Hardison,Sheryl F. Kelsey,Bonnie H. Weiner,Alice K. Jacobs,George Sopko. &nbspCirculation: Journal of the American Heart Association . 2002 (20)

[7] Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment[J] . John J.P. Kastelein,Wim A. van der Steeg,Ingar Holme,Michael Gaffney,Nilo B. Cater,Philip Barter,Prakash Deedwania,Anders G. Olsson,S Matthijs Boekholdt,David A. Demicco,Michael Szarek,John C. LaRosa,Terje R. Pedersen,Scott M. Grundy. &nbspCirculation . 2008 (23)

[1] Intensive lipid lowering with atorvastatin in patients with stable coronary disease. LaRosa JC,Grundy SM,Waters DD,et al. The New England Journal of Medicine . 2005

[2] Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins:a meta-analysis. Boekhold SM,Aresenault BJ,Mora S,et al. The Journal of The American Medical Association . 2012

[3] Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Cui Y,Blumenthal RS,Flaws JA,et al. Archives of Internal Medicine . 2001

[4] ESC/EAS Guidelines for the management of dyslipidaemias:theTask Force for the management of dyslipidaemias of theEuropean Society of Cardiology(ESC)and the EuropeanAtherosclerosis Society(EAS). European Association for Cardiovascular Prevention&RE-HABILITATION,,REINER Z,CATAPANO AL,et al. European Heart Journal . 2011

[5] Beyond Low-Density Lipoprotein Cholesterol[J] . Benoit J. Arsenault,Jamal S. Rana,Erik S.G. Stroes,Jean-Pierre Després,Prediman K. Shah,John J.P. Kastelein,Nicholas J. Wareham,S. Matthijs Boekholdt,Kay-Tee Khaw. &nbspJournal of the American College of Cardiology . 2010 (1)

[6] Non–High-Density Lipoprotein Cholesterol Levels Predict Five-Year Outcome in the Bypass Angioplasty Revascularization Investigation (BARI)[J] . Vera Bittner,Regina Hardison,Sheryl F. Kelsey,Bonnie H. Weiner,Alice K. Jacobs,George Sopko. &nbspCirculation: Journal of the American Heart Association . 2002 (20)

[7] Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment[J] . John J.P. Kastelein,Wim A. van der Steeg,Ingar Holme,Michael Gaffney,Nilo B. Cater,Philip Barter,Prakash Deedwania,Anders G. Olsson,S Matthijs Boekholdt,David A. Demicco,Michael Szarek,John C. LaRosa,Terje R. Pedersen,Scott M. Grundy. &nbspCirculation . 2008 (23)